A biopharmaceutical organization focused on discovering.

The next patent addresses a diagnostic test based on measurement of the abundance of a single protein, known as CD68, in tumor samples. Both tests can be performed using preserved or clean tumor biopsy material. AVEO’s successful usage of its genetically manufactured mouse models to discover these human-relevant biomarkers demonstrates the potential of AVEO’s preclinical tumor models in individual response prediction. ‘We believe these tests reflect different aspects of the same underlying tumor biology and have potential for advancement as companion diagnostics in a broad selection of tumor types. Ongoing study involving these tests can help AVEO make educated decisions as we explore the usage of these biomarkers inside our clinical programs,’ commented Tuan Ha-Ngoc, president and ceo of AVEO Pharmaceuticals.‘We are exploring opportunities to supply our cells to those establishments.

3rd Annual Pharma Pricing Strategies – Jacob Fleming Group january 2008 15th-16th, Hotel Radisson SAS, Rome, Italy This event shall bring together the Pharma Industry experts to benchmark the very best practices in health economics, and their encounter with advantage reference and evaluations pricing approach. During two days, the participants will have the opportunity to compare and contrast different reimbursement and prices policies across the European markets. Setting the right price and making certain the product is normally adequately reimbursed is vital for a company’s profitability.